Despite the complexities of managing and treating bronchiectasis, recent research developments provide reasons for optimism. The FDA has set Aug. 12 as an action date for its review of brensocatib, which has the potential to be the first FDA-approved medication for bronchiectasis. Dan Belz, MD, MPH, spoke with ATS Conference News about how these developments,…

According to the World Health Organization, chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death globally, accounting for approximately five percent of deaths worldwide in 2021. The ATS International Conference is a rare opportunity for health specialists from around the globe to share insights and collectively address the most prevalent challenges in…

The ATS 2025 International Conference offers a robust scientific program featuring several scientific symposia, abstract presentations, and Meet the Expert sessions addressing the latest investigative findings and clinical insights for bronchiectasis and COPD.